Literature DB >> 19679875

Fenfluramine disrupts the mitral valve interstitial cell response to serotonin.

Jeanne M Connolly1, Marina A Bakay, James T Fulmer, Robert C Gorman, Joseph H Gorman, Mark A Oyama, Robert J Levy.   

Abstract

Serotonin (5HT) receptor signaling and 5HT-related agents, such as the anorexogen fenfluramine (Fen), have been associated with heart valve disease. We investigated the hypothesis that Fen may disrupt mitral valve interstitial cell (MVIC) homeostasis through its effects on mitogenesis and extracellular matrix biosynthesis. Normal and myxomatous mitral valves, both human and canine, were harvested, and primary MVIC cultures were established. 5HT caused increased phosphorylation of extracellular signal-related kinase in MVIC; Fen alone did not. However, Fen combined with 5HT increased the level of MVIC extracellular signal-related kinase, when compared with 5HT alone. In addition, MVIC mitogenesis per (3)H-thymidine ((3)HTdR) demonstrated a 5HT dose-dependent increase, with no effect of Fen alone. In contrast, Fen combined with 5HT inhibited the MVIC (3)HTdR response when compared with 5HT alone. Furthermore, fluoxetine, a 5HT transporter inhibitor, while having no effect alone, suppressed Fen-5HT (3)HTdR inhibition when administered with Fen plus 5HT. Finally, MVIC incorporations of (3)H-proline and (3)H-glucosamine, measures of extracellular matrix collagen and glycosaminoglycan respectively, were increased with 5HT alone; however, Fen did not affect MVIC glycosaminoglycan or collagen either alone or in combination with 5HT. Taken together, the ratios of (3)H-proline or (3)H-glycosaminoglycan to (3)HTdR in MVIC, normalized to 5HT alone, demonstrated a significant imbalance of extracellular matrix production versus proliferation in MVIC cultures with Fen plus 5HT exposure. This imbalance may explain in part the pathophysiology of Fen-related mitral valve disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19679875      PMCID: PMC2731118          DOI: 10.2353/ajpath.2009.081101

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

Review 1.  Neurotransmitter transporters: fruitful targets for CNS drug discovery.

Authors:  L Iversen
Journal:  Mol Psychiatry       Date:  2000-07       Impact factor: 15.992

2.  Differential use of Alcian blue and toluidine blue dyes for the quantification and isolation of anionic glycoconjugates from cell cultures: application to proteoglycans and a high-molecular-weight glycoprotein synthesized by articular chondrocytes.

Authors:  D E Terry; R K Chopra; J Ovenden; T P Anastassiades
Journal:  Anal Biochem       Date:  2000-10-15       Impact factor: 3.365

3.  Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves.

Authors:  E Rabkin; M Aikawa; J R Stone; Y Fukumoto; P Libby; F J Schoen
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

4.  Association between selective serotonin-reuptake inhibitor therapy and heart valve regurgitation.

Authors:  S T Mast; K R Gersing; K J Anstrom; K R Krishnan; R M Califf; J G Jollis
Journal:  Am J Cardiol       Date:  2001-04-15       Impact factor: 2.778

5.  Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.

Authors:  R B Rothman; M H Baumann; J E Savage; L Rauser; A McBride; S J Hufeisen; B L Roth
Journal:  Circulation       Date:  2000-12-05       Impact factor: 29.690

6.  Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.

Authors:  L W Fitzgerald; T C Burn; B S Brown; J P Patterson; M H Corjay; P A Valentine; J H Sun; J R Link; I Abbaszade; J M Hollis; B L Largent; P R Hartig; G F Hollis; P C Meunier; A J Robichaud; D W Robertson
Journal:  Mol Pharmacol       Date:  2000-01       Impact factor: 4.436

7.  Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine.

Authors:  B K Shively; C A Roldan; E A Gill; T Najarian; S B Loar
Journal:  Circulation       Date:  1999-11-23       Impact factor: 29.690

8.  Molecular determinants for the interaction of the valvulopathic anorexigen norfenfluramine with the 5-HT2B receptor.

Authors:  Vincent Setola; Malgorzata Dukat; Richard A Glennon; Bryan L Roth
Journal:  Mol Pharmacol       Date:  2005-04-14       Impact factor: 4.436

Review 9.  Mitral valve prolapse in the dog: a model of mitral valve prolapse in man.

Authors:  H D Pedersen; J Häggström
Journal:  Cardiovasc Res       Date:  2000-08       Impact factor: 10.787

10.  Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.

Authors:  R B Rothman; J B Redmon; S K Raatz; C A Kwong; J E Swanson; J P Bantle
Journal:  Am J Cardiol       Date:  2000-04-01       Impact factor: 2.778

View more
  16 in total

1.  Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness.

Authors:  Kartik Balachandran; Marina A Bakay; Jeanne M Connolly; Xuemei Zhang; Ajit P Yoganathan; Robert J Levy
Journal:  Ann Thorac Surg       Date:  2011-07       Impact factor: 4.330

Review 2.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

3.  Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation.

Authors:  Kathryn H Driesbaugh; Emanuela Branchetti; Juan B Grau; Samuel J Keeney; Kimberly Glass; Mark A Oyama; Nancy Rioux; Salma Ayoub; Michael S Sacks; John Quackenbush; Robert J Levy; Giovanni Ferrari
Journal:  J Mol Cell Cardiol       Date:  2017-12-30       Impact factor: 5.000

4.  Developmental basis for filamin-A-associated myxomatous mitral valve disease.

Authors:  Kimberly Sauls; Annemarieke de Vlaming; Brett S Harris; Katherine Williams; Andy Wessels; Robert A Levine; Susan A Slaugenhaupt; Richard L Goodwin; Luigi Michele Pavone; Jean Merot; Jean-Jacques Schott; Thierry Le Tourneau; Thomas Dix; Sean Jesinkey; Yuanyi Feng; Christopher Walsh; Bin Zhou; Scott Baldwin; Roger R Markwald; Russell A Norris
Journal:  Cardiovasc Res       Date:  2012-07-25       Impact factor: 10.787

5.  Inflammatory regulation of valvular remodeling: the good(?), the bad, and the ugly.

Authors:  Gretchen J Mahler; Jonathan T Butcher
Journal:  Int J Inflam       Date:  2011-07-18

6.  Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.

Authors:  S E Cremer; G E Singletary; L H Olsen; K Wallace; J Häggström; I Ljungvall; K Höglund; C A Reynolds; N Pizzinat; M A Oyama
Journal:  J Vet Intern Med       Date:  2014-08-21       Impact factor: 3.333

Review 7.  Mechanotransduction Mechanisms in Mitral Valve Physiology and Disease Pathogenesis.

Authors:  Leah A Pagnozzi; Jonathan T Butcher
Journal:  Front Cardiovasc Med       Date:  2017-12-22

8.  CC-chemokine receptor 7 and its ligand CCL19 promote mitral valve interstitial cell migration and repair.

Authors:  Xiaozhi Wang; Liang Wang; Liping Miao; Rong Zhao; Yanhu Wu; Xiangqing Kong
Journal:  J Biomed Res       Date:  2015-09-09

Review 9.  Comparative Transcriptomic Profiling and Gene Expression for Myxomatous Mitral Valve Disease in the Dog and Human.

Authors:  Greg R Markby; Kim M Summers; Vicky E MacRae; Brendan M Corcoran
Journal:  Vet Sci       Date:  2017-07-17

10.  Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve.

Authors:  Jaime Ibarrola; Mattie Garaikoetxea; Amaia Garcia-Peña; Lara Matilla; Eva Jover; Benjamin Bonnard; Maria Cuesta; Amaya Fernández-Celis; Frederic Jaisser; Natalia López-Andrés
Journal:  Int J Mol Sci       Date:  2020-07-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.